---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-004159"
form_type: "8-K"
ticker: "KURA"
cik: "0001422143"
company_name: "Kura Oncology, Inc."
filed_at: "2023-01-09T23:59:59+00:00"
generated_at: "2026-06-20T17:39:07.383167+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "low"
source: SEC EDGAR
---

# Kura Oncology reports preliminary cash balance of ~$438M as of Dec 31, 2022

## Summary
- Preliminary unaudited cash, cash equivalents and short-term investments were approximately $438 million.
- Cash balance is subject to completion of financial closing and audit; actual results may differ.
- Company updated its corporate presentation materials (Exhibit 99.1), but substantive details not provided in filing.

## SEC filing metadata
- accession: 0001193125-23-004159
- form_type: 8-K
- ticker: KURA
- cik: 0001422143
- company_name: Kura Oncology, Inc.
- filed_at: 2023-01-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: low
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1422143/000119312523004159/0001193125-23-004159-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1422143/000119312523004159/d446484d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-004159
- JSON: https://secwatch.observer/filing/0001193125-23-004159.json
- Plain text: https://secwatch.observer/filing/0001193125-23-004159.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.